No registrations found.
ID
Source
Brief title
Health condition
Diabetes, obesity, insulin resistance,
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Peripheral glucose uptake (Rd)
- Ganglisosides concentration in muscle and adipose tissue
Secondary outcome
- Plasma concentration of glucoregulatory hormones
- Energy expenditure
- Carbohydrate oxidation and fat oxidation
- VO2 max
- Muscle fiber type
Background summary
Gangliosides reside within the plasma membrane and are able to modulate insulin signaling at the level of the insulin receptor. The most abundant ganglioside is GM3. Recently, we and others have shown in rats that pharmacologically reducing GM2 and GM3 levels results in amelioration of high fat diet induced insulin resistance. In this study we want to explore if gangliosides are elevated in muscle and adipose tissue of obese subjects inslin resistant subjects compared to matched healthy controls.
Study objective
We hypothesize that membrane-residing gangliosides are elevated in obese insulin resistant subjects and correlate to peripheral insulin resistance.
Furthermore, we hypothesize that the perturbation of the insulin signaling cascade by elevated gangliosides is caused by a reduced phosphorylation of the insulin receptor.
Study design
N/A
Intervention
None:
This is a comparitive study; 10 obese men mached for gender and age with 10 lean men.
F5-162 Endocrinology and Metabolism
M. Brands
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5662663
m.brands@amc.uva.nl
F5-162 Endocrinology and Metabolism
M. Brands
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5662663
m.brands@amc.uva.nl
Inclusion criteria
Inclusion criteria for all participants
1. Written informed consent
2. Caucasian
3. Able to keep a normal day and night rhythm during the study period (i.e. no shift work)
4. Stable weight for at least 3 months
5. Age 20-55 years
Inclusion criteria for healthy volunteers:
1. 20 ¡Ü BMI ¡Ü 25 kg/m2
2. Fasting glucose level of < 5.6 mmol/L, in addition to a glucose level of < 7.8 mmol/L at 2 hours after intake of 75 g glucose (OGTT).
Inclusion criteria for obese subjects:
1. BMI >30 kg/m2
2. Fasting glucose level of < 7 mmol/L, in addition to a glucose level of < 11.0 mmol/L at 2 hours after intake of 75 g glucose (OGTT).
3. HOMA IR > 2.7
Exclusion criteria
Exclusion criteria for all participants:
1. Participation in an investigational drug trial within 90 days prior to our study
2. history of or current abuse of drugs or alcohol (>14 U/week)
3. Smoking
4. Vigorous physical activity
5. Family history of DM II
6. Familial dyslipidemia
7. Any medical condition except hypertension and dyslipidemia in the obese group
8. Use of any medication except for anti-hypertensives, excluding ACE-inhibitors/AII-antagonists.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1471 |
| NTR-old | NTR1540 |
| Other | : MEC 08/280 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |